EXANTA
| Title | Journal |
|---|---|
| Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. | Journal of applied toxicology : JAT 20160101 |
| The promise of novel direct oral anticoagulants. | Best practice & research. Clinical haematology 20120901 |
| Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. | Archives of internal medicine 20120423 |
| Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. | Thrombosis research 20120401 |
| Two-year carcinogenicity studies with the oral direct thrombin inhibitor ximelagatran in the rat and the mouse. | International journal of toxicology 20120101 |
| Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. | Journal of internal medicine 20110901 |
| Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban. | American journal of therapeutics 20110701 |
| Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers. | Journal of clinical pharmacology 20110501 |
| Mechanisms of drug-induced liver injury: from bedside to bench. | Nature reviews. Gastroenterology & hepatology 20110401 |
| Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. | Journal of the American College of Cardiology 20110111 |
| Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. | PloS one 20110101 |
| [Novel anticoagulants for stroke prevention in atrial fibrillation]. | Deutsche medizinische Wochenschrift (1946) 20101101 |
| The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. | Thrombosis research 20101001 |
| Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. | Thrombosis research 20101001 |
| Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? | The American journal of medicine 20100901 |
| Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. | Thrombosis and haemostasis 20100901 |
| The application of metabonomics to predict drug-induced liver injury. | Clinical pharmacology and therapeutics 20100901 |
| Will direct thrombin inhibition change the boundaries of oral anti-coagulation? | QJM : monthly journal of the Association of Physicians 20100601 |
| Old versus new anticoagulants: focus on pharmacology. | Recent patents on cardiovascular drug discovery 20100601 |
| Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. | Nature reviews. Drug discovery 20100601 |
| Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. | The Cochrane database of systematic reviews 20100414 |
| Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model. | Pharmaceutical research 20100401 |
| Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. | Drug metabolism and disposition: the biological fate of chemicals 20100301 |
| Drug-induced liver injury in humans: the case of ximelagatran. | Handbook of experimental pharmacology 20100101 |
| Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20091201 |
| A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. | Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20091201 |
| Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. | Toxicology in vitro : an international journal published in association with BIBRA 20091001 |
| What can ongoing clinical trials of anticoagulants demonstrate? | Journal of cardiovascular medicine (Hagerstown, Md.) 20090801 |
| Novel oral anticoagulants and diet: the potential for interaction. | American journal of hematology 20090401 |
| Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety. | Annals of hematology 20090201 |
| Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LC-MS/MS) of ximelagatran and its metabolites in a complex matrix. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115 |
| Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. | Thrombosis research 20090101 |
| Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101 |
| Digitalis: a dangerous drug in atrial fibrillation? | Heart (British Cardiac Society) 20081201 |
| [New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics]. | Medicina clinica 20081101 |
| Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. | Toxicology in vitro : an international journal published in association with BIBRA 20080901 |
| Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. | Drug metabolism and disposition: the biological fate of chemicals 20080801 |
| Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. | Clinical orthopaedics and related research 20080801 |
| Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. | Journal of internal medicine 20080701 |
| Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures. | Expert opinion on drug safety 20080701 |
| Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. | International journal of clinical pharmacology and therapeutics 20080701 |
| Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. | The pharmacogenomics journal 20080601 |
| Prevention of venous thromboembolism in the geriatric patient. | Cardiology clinics 20080501 |
| Chronic antithrombotic therapy in post-myocardial infarction patients. | Cardiology clinics 20080501 |
| Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080501 |
| Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. | The Cochrane database of systematic reviews 20080416 |
| Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. | Toxicology in vitro : an international journal published in association with BIBRA 20080401 |
| Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. | Clinical orthopaedics and related research 20080301 |
| Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. | Heart (British Cardiac Society) 20080201 |
| Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. | American heart journal 20080201 |
| Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. | Seminars in thrombosis and hemostasis 20080201 |
| A multinational investigation of time and traveling costs in attending anticoagulation clinics. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101 |
| Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. | International journal of cardiology 20071115 |
| Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. | Stroke 20071101 |
| Nonbleeding complications of unfractionated and low-molecular weight heparins. | Clinical advances in hematology & oncology : H&O 20071101 |
| Development of oral anticoagulants. | British journal of clinical pharmacology 20070901 |
| Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? | Stroke 20070901 |
| Beyond unfractionated heparin and warfarin: current and future advances. | Circulation 20070731 |
| Re: early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. | European heart journal 20070701 |
| Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story. | Stroke 20070701 |
| Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20070701 |
| The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. | Expert opinion on drug safety 20070701 |
| Determination of ximelagatran, melagatran and two intermediary metabolites in plasma by mixed-mode solid phase extraction and LC-MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601 |
| Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. | European journal of clinical pharmacology 20070601 |
| [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. | Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20070601 |
| [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. | Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20070601 |
| [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. | Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20070601 |
| Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. | Stroke 20070301 |
| Effect of hypertension on anticoagulated patients with atrial fibrillation. | European heart journal 20070301 |
| Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. | European heart journal 20070301 |
| [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. | Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20070301 |
| Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. | European journal of heart failure 20070101 |
| Current challenges of anticoagulant treatment. | Romanian journal of internal medicine = Revue roumaine de medecine interne 20070101 |
| Direct thrombin inhibitors - a survey of recent developments. | Cellular and molecular life sciences : CMLS 20061201 |
| Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials. | Sao Paulo medical journal = Revista paulista de medicina 20061107 |
| Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. | American heart journal 20061101 |
| [Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors]. | Giornale italiano di cardiologia (2006) 20061101 |
| [Ximelagatran]. | Nihon rinsho. Japanese journal of clinical medicine 20061028 |
| The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. | Contemporary clinical trials 20061001 |
| Optimising stroke prevention in non-valvular atrial fibrillation. | Expert opinion on pharmacotherapy 20061001 |
| Trials and tribulations of noninferiority: the ximelagatran experience. | Journal of the American College of Cardiology 20060905 |
| Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. | European heart journal 20060801 |
| Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. | Archives of internal medicine 20060626 |
| [Deep vein thrombosis: new drugs and future therapeutic perspectives]. | Revista clinica espanola 20060601 |
| [Old burdens and new perspectives of the long-term anticoagulant therapy]. | Orvosi hetilap 20060514 |
| Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. | Drug metabolism and disposition: the biological fate of chemicals 20060501 |
| The risks of warfarin use in the elderly. | Expert opinion on drug safety 20060501 |
| Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. | The Journal of bone and joint surgery. American volume 20060501 |
| Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. | Archives of internal medicine 20060424 |
| 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. | Pharmacoepidemiology and drug safety 20060401 |
| Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. | British journal of haematology 20060401 |
| Hy's law: predicting serious hepatotoxicity. | Pharmacoepidemiology and drug safety 20060401 |
| How can 'Hy's law' help the clinician? | Pharmacoepidemiology and drug safety 20060401 |
| Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. | European journal of clinical pharmacology 20060301 |
| Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344). | The British journal of surgery 20060301 |
| Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344). | The British journal of surgery 20060301 |
| Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344). | The British journal of surgery 20060301 |
| Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. | Thrombosis and haemostasis 20060301 |
| Lack of trophic pancreatic effects in humans with long-term administration of ximelagatran. | Pancreas 20060301 |
| Clinical trials of new anticoagulants. | Vnitrni lekarstvi 20060301 |
| Ximelagatran: direct thrombin inhibitor. | Vascular health and risk management 20060301 |
| Thrombolytics, anticoagulants, and antiplatelet agents. | Stroke 20060201 |
| Food-drug interactions. | International journal of cardiology 20060126 |
| Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. | Thrombosis research 20060101 |
| Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. | Clinical pharmacokinetics 20060101 |
| Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran. | Clinical pharmacokinetics 20060101 |
| Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. | Cerebrovascular diseases (Basel, Switzerland) 20060101 |
| Ximelagatran. | Drugs of today (Barcelona, Spain : 1998) 20060101 |
| Ximelagatran: an eulogy. | Thrombosis research 20060101 |
| Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. | International journal of toxicology 20060101 |
| Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. | Clinical pharmacokinetics 20060101 |
| Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. | Pathophysiology of haemostasis and thrombosis 20060101 |
| Trials and tribulations of non-inferiority: the ximelagatran experience. | Journal of the American College of Cardiology 20051206 |
| New anticoagulants for venous thromboembolic disease. | Current opinion in cardiology 20051101 |
| Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. | The British journal of surgery 20051101 |
| [The new antithrombotic agents]. | Presse medicale (Paris, France : 1983) 20051022 |
| [Preventing cerebrovascular accidents during atrial fibrillation]. | Presse medicale (Paris, France : 1983) 20051022 |
| New anticoagulants in ischemic heart disease. | Presse medicale (Paris, France : 1983) 20051022 |
| Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. | Journal of thrombosis and haemostasis : JTH 20051001 |
| Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. | The Journal of bone and joint surgery. American volume 20051001 |
| Will this be the end of the anticoagulation clinic for patients with atrial fibrillation? | Current drug targets. Cardiovascular & haematological disorders 20051001 |
| Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. | Thrombosis and haemostasis 20051001 |
| A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. | Journal of clinical pharmacology 20050901 |
| Anticoagulation: new challenges, old drugs. | Current cardiology reports 20050901 |
| Heparin and other rapidly acting anticoagulants. | Seminars in vascular surgery 20050901 |
| Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. | Thrombosis and haemostasis 20050901 |
| New antithrombotics in the prevention of thromboembolic disease. | European journal of internal medicine 20050801 |
| New anticoagulants. | Journal of thrombosis and haemostasis : JTH 20050801 |
| Ximelagatran as a new oral anticoagulant for thrombosis. | Seminars in vascular medicine 20050801 |
| Discovery of ximelagatran in an historical perspective. | Seminars in vascular medicine 20050801 |
| Mechanism of action of the oral direct thrombin inhibitor ximelagatran. | Seminars in vascular medicine 20050801 |
| Pharmacokinetics and pharmacodynamics of ximelagatran. | Seminars in vascular medicine 20050801 |
| Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol. | Seminars in vascular medicine 20050801 |
| A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran. | Seminars in vascular medicine 20050801 |
| Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. | Seminars in vascular medicine 20050801 |
| Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. | Seminars in vascular medicine 20050801 |
| Prevention of stroke in patients with atrial fibrillation. | Seminars in vascular medicine 20050801 |
| Ximelagatran in the clinic: practical management of patients. | Seminars in vascular medicine 20050801 |
| A profit-thinner. Hospitals, docs await substitute for risky warfarin. | Modern healthcare 20050725 |
| Uncertain times for oral anticoagulation therapy. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050715 |
| Ximelagatran: an orally active direct thrombin inhibitor. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050715 |
| Ximelagatran for stroke prevention in atrial fibrillation. | Expert review of cardiovascular therapy 20050701 |
| Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. | Expert review of cardiovascular therapy 20050701 |
| A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era.. | American heart journal 20050701 |
| [Ximelagatran: hopes and controversies]. | Journal des maladies vasculaires 20050701 |
| Safety of ximelagatran. | JAMA 20050615 |
| Cost-effectiveness of ximelagatran for stroke prevention. | JAMA 20050615 |
| The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20050601 |
| Direct thrombin inhibitors: pharmacology and clinical relevance. | Anaesthesia 20050601 |
| Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. | Postgraduate medical journal 20050601 |
| [Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?]. | Ugeskrift for laeger 20050523 |
| The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation. | BJOG : an international journal of obstetrics and gynaecology 20050501 |
| Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration. | Journal of thrombosis and haemostasis : JTH 20050501 |
| A better way to prevent blood clots? A drug derived from cobra venom offers an alternative to warfarin, although liver problems temper its benefits. | Harvard heart letter : from Harvard Medical School 20050501 |
| Antithrombotic strategies for the management of non-valvular atrial fibrillation. | International journal of cardiology 20050420 |
| Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes? | Heart (British Cardiac Society) 20050401 |
| Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. | Clinical pharmacology and therapeutics 20050401 |
| [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]. | Recenti progressi in medicina 20050401 |
| [A thrombin inhibitor called ximelagatran]. | Presse medicale (Paris, France : 1983) 20050312 |
| The direct thrombin inhibitor melagatran/ximelagatran. | The Medical journal of Australia 20050307 |
| Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. | Cardiovascular drugs and therapy 20050301 |
| New anticoagulants for the prevention and treatment of venous thromboembolism. | Vascular health and risk management 20050301 |
| Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. | JAMA 20050209 |
| Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. | JAMA 20050209 |
| Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. | JAMA 20050209 |
| Ximelagatran--promises and concerns. | JAMA 20050209 |
| [Atrial fibrillation and thromboprophylaxis in elderly patients]. | Zeitschrift fur Kardiologie 20050201 |
| Prevention of embolism among patients with atrial fibrillation. | Current neurology and neuroscience reports 20050201 |
| New ways to prevent venous thromboembolism--the pentasaccharide fondaparinux and the thrombin inhibitor ximelagatran--a review. | Acta chirurgica Belgica 20050201 |
| Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. | Journal of the American College of Cardiology 20050104 |
| A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. | Thrombosis research 20050101 |
| Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. | Thrombosis research 20050101 |
| Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. | American heart journal 20050101 |
| Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. | American heart journal 20050101 |
| Thrombin-directed inhibitors: pharmacology and clinical use. | American heart journal 20050101 |
| Novel constructs for thrombin inhibition. | American heart journal 20050101 |
| Oral anticoagulation: challenges in the case-management setting. | Lippincott's case management : managing the process of patient care 20050101 |
| Ximelagatran--a promising new drug in thromboembolic disorders. | Current pharmaceutical design 20050101 |
| Hepatic findings in long-term clinical trials of ximelagatran. | Drug safety 20050101 |
| Anticoagulation for atrial fibrillation in the elderly. | The American journal of geriatric cardiology 20050101 |
| Introduction. | Pathophysiology of haemostasis and thrombosis 20050101 |
| Ximelagatran in orthopaedic surgery. | Pathophysiology of haemostasis and thrombosis 20050101 |
| The role of ximelagatran in the treatment of venous thromboembolism. | Pathophysiology of haemostasis and thrombosis 20050101 |
| Preventing stroke in atrial fibrillation: the SPORTIF programme. | Pathophysiology of haemostasis and thrombosis 20050101 |
| Anticoagulant use in patients with chronic renal impairment. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
| New trends in anticoagulant treatments. | Lupus 20050101 |
| Ximelagatran: a new type of oral anticoagulant. | International journal of technology assessment in health care 20050101 |
| Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. | Current pharmaceutical design 20050101 |
| Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. | Current pharmaceutical design 20050101 |
| [Novel possibilities of antithrombotic therapy in patients with chronic heart failure]. | Kardiologiia 20050101 |
| Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. | Clinical pharmacokinetics 20050101 |
| [New antithrombotic drugs: fondaparinux, idraparinux, ximelagatran]. | Przeglad lekarski 20050101 |
| Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge? | Cardiovascular drug reviews 20050101 |
| [Stroke prevention in atrial fibrillation -- transfer of study results to the practice]. | Wiener klinische Wochenschrift 20041230 |
| [New anticoagulants in clinical practice]. | Orvosi hetilap 20041205 |
| Ximelagatran data fail to impress FDA. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20041201 |
| Potential effect of ximelagatran use on an anticoagulation clinic. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20041201 |
| Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. | Seminars in thrombosis and hemostasis 20041201 |
| Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. | The American journal of managed care 20041201 |
| Ximelagatran: an oral direct thrombin inhibitor. | The Annals of pharmacotherapy 20041101 |
| Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study. | Journal of thrombosis and haemostasis : JTH 20041101 |
| The direct thrombin inhibitor melagatran/ximelagatran. | The Medical journal of Australia 20041018 |
| Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. | European journal of haematology 20041001 |
| Preparing for the post-warfarin generation of antithrombotics. | The American journal of managed care 20041001 |
| Tales of two oral anticoagulants from natural product research and their impact on clinical pharmacy. | Pharmacotherapy 20041001 |
| Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics. | Pharmacotherapy 20041001 |
| The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. | Pharmacotherapy 20041001 |
| The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism. | Pharmacotherapy 20041001 |
| [Cardiac indications for oral anticoagulation]. | Praxis 20040915 |
| New approaches to anticoagulation in atrial fibrillation. | Current cardiology reports 20040901 |
| A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. | Journal of clinical pharmacology 20040901 |
| Ximelagatran: a new antithrombotic option in atrial fibrillation. | Journal of cardiovascular pharmacology and therapeutics 20040901 |
| Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. | Current medicinal chemistry 20040901 |
| Is that it, then, for blockbuster drugs? | Lancet (London, England) 20040901 |
| [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins]. | Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20040901 |
| Acute reversal of anticoagulant-induced bleeding complications. | Clinical advances in hematology & oncology : H&O 20040901 |
| New anticoagulants for treatment of venous thromboembolism. | Circulation 20040831 |
| Will oral antithrombin agents replace warfarin? | Heart (British Cardiac Society) 20040801 |
| Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin. | Thrombosis and haemostasis 20040801 |
| Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations. | Anaesthesia 20040801 |
| No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. | Journal of clinical pharmacology 20040801 |
| No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. | Journal of clinical pharmacology 20040801 |
| A new oral anticoagulant: the 50-year challenge. | Nature reviews. Drug discovery 20040801 |
| Challenges in the prevention of venous thromboembolism in the elderly. | Journal of thrombosis and haemostasis : JTH 20040801 |
| New trends in anticoagulant therapy. | The Israel Medical Association journal : IMAJ 20040801 |
| [Prevention and treatment of deep vein thrombosis with ximelagatran]. | Deutsche medizinische Wochenschrift (1946) 20040723 |
| Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. | Journal of thrombosis and haemostasis : JTH 20040701 |
| Aspirin bias in SPORTIF III trial. | Lancet (London, England) 20040619 |
| The beginning of the end of warfarin? | The Medical journal of Australia 20040607 |
| [Modern anticoagulation. Problems of the proven, hope for the new]. | Der Internist 20040601 |
| Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation. | Stroke 20040601 |
| The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials. | Expert opinion on pharmacotherapy 20040601 |
| Anticoagulants. Oral drug options may expand. | Mayo Clinic health letter (English ed.) 20040601 |
| [The new anticoagulants are here!]. | Revue des maladies respiratoires 20040601 |
| Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin. | Expert opinion on investigational drugs 20040501 |
| [Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs]. | Journal des maladies vasculaires 20040501 |
| SSR182289A, a selective and potent orally active thrombin inhibitor. | Bioorganic & medicinal chemistry 20040401 |
| The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. | Journal of clinical pharmacology 20040401 |
| Ximelagatran: the first oral direct thrombin inhibitor. | Expert opinion on investigational drugs 20040401 |
| Anticoagulation in atrial fibrillation. | Medicine and health, Rhode Island 20040401 |
| Antithrombotic therapies for stroke prevention in atrial fibrillation. | Minerva cardioangiologica 20040401 |
| Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. | Current medical research and opinion 20040301 |
| Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. | Expert review of cardiovascular therapy 20040301 |
| Ximelagatran: a new oral anticoagulant. | Best practice & research. Clinical haematology 20040301 |
| Fighting clots before they form. A new drug may end one of many patients' biggest hassles. | Heart advisor 20040301 |
| [Ximelagatran: a promising new drug for oral anticoagulation]. | Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 20040301 |
| Ximelagatran or warfarin in atrial fibrillation? | Lancet (London, England) 20040227 |
| Ximelagatran or warfarin in atrial fibrillation? | Lancet (London, England) 20040227 |
| Ximelagatran or warfarin in atrial fibrillation? | Lancet (London, England) 20040227 |
| Ximelagatran or warfarin in atrial fibrillation? | Lancet (London, England) 20040227 |
| Ximelagatran versus warfarin after total knee replacement. | The New England journal of medicine 20040205 |
| Ximelagatran for secondary prevention of venous thromboembolism. | The New England journal of medicine 20040205 |
| Ximelagatran versus warfarin after total knee replacement. | The New England journal of medicine 20040205 |
| Ximelagatran versus warfarin after total knee replacement. | The New England journal of medicine 20040205 |
| Ximelagatran for secondary prevention of venous thromboembolism. | The New England journal of medicine 20040205 |
| Advances in stroke 2003: introduction. | Stroke 20040201 |
| Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation? | Stroke 20040201 |
| Testing an alternative to warfarin. | Harvard heart letter : from Harvard Medical School 20040201 |
| Current anticoagulation therapy--a GP guide. | The Practitioner 20040201 |
| Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? | Current opinion in cardiology 20040101 |
| Oral thrombin inhibitor ximelagatran. | Methods in molecular medicine 20040101 |
| Trials of newer approaches to anticoagulation in atrial fibrillation. | Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20040101 |
| Molecule of the month. Ximelagatran. | Drug news & perspectives 20040101 |
| Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. | Drugs 20040101 |
| The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. | Thrombosis research 20040101 |
| [Ximelagatran (Exanta). Laboratory: Astra Zeneca]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101 |
| Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20040101 |
| Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation. | Reviews in cardiovascular medicine 20040101 |
| Treatment of venous thromboembolism: duration and new options. | The hematology journal : the official journal of the European Haematology Association 20040101 |
| Ximelagatran: light at the end of the tunnel or the next tunnel? | The American journal of geriatric cardiology 20040101 |
| Results of THRIVE treatent study show that ximelagatran is safe and effective against throbosis. | The journal of supportive oncology 20040101 |
| Advances in DVT prophylaxis and management in major orthopaedic surgery. | Surgical technology international 20040101 |
| [Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis]. | Kardiologiia 20040101 |
| New blood thinner offers first potential alternative in 50 years: ximelagatran. | The Journal of cardiovascular nursing 20040101 |
| Ximelagatran, a new oral anticoagulant--how will it affect laboratory practice? A clinical perspective. | Laboratory hematology : official publication of the International Society for Laboratory Hematology 20040101 |
| Ximelagatran, a new oral anticoagulant--how will it affect laboratory practice? A laboratory perspective. | Laboratory hematology : official publication of the International Society for Laboratory Hematology 20040101 |
| Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics. | The American heart hospital journal 20040101 |
| Ximelagatran-an oral direct thrombin inhibitor. | Progress in cardiovascular nursing 20040101 |
| Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. | Drugs 20040101 |
| Clinical experience with ximelagatran in orthopaedic surgery. | Drugs 20040101 |
| Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran. | Drugs 20040101 |
| Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. | Drugs 20040101 |
| Preface. Ximelagatran and oral direct thrombin inhibition. | Reviews in cardiovascular medicine 20040101 |
| The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. | Reviews in cardiovascular medicine 20040101 |
| Changing the guard in long-term anticoagulation: clinical and economic implications. | Reviews in cardiovascular medicine 20040101 |
| New possibilities in anticoagulant management of atrial fibrillation. | Reviews in cardiovascular medicine 20040101 |
| Reducing cardiac events after acute coronary syndromes. | Reviews in cardiovascular medicine 20040101 |
| Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition. | Reviews in cardiovascular medicine 20040101 |
| Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery. | Clinical drug investigation 20040101 |
| Oral anticoagulation: preparing for change. | Journal of the American Medical Directors Association 20040101 |
| The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. | Journal of thrombosis and haemostasis : JTH 20031201 |
| [Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects]. | Der Anaesthesist 20031201 |
| [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation]. | Revue medicale de Liege 20031201 |
| A review of the clinical uses of ximelagatran in thrombosis syndromes. | Journal of thrombosis and thrombolysis 20031201 |
| [Anticoagulation in atrial fibrillation. Instead of costly therapy control soon a tablet for all?]. | MMW Fortschritte der Medizin 20031127 |
| Can we pull the plug on warfarin in atrial fibrillation? | Lancet (London, England) 20031122 |
| Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. | Lancet (London, England) 20031122 |
| [New anticoagulants in the treatment of venous thrombo-embolic disease]. | La Revue de medecine interne 20031101 |
| [EBM of cerebral infarction: message from mega-studies]. | Rinsho shinkeigaku = Clinical neurology 20031101 |
| Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy. | IDrugs : the investigational drugs journal 20031101 |
| Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. | The New England journal of medicine 20031030 |
| Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. | The New England journal of medicine 20031030 |
| Treating thrombosis in the 21st century. | The New England journal of medicine 20031030 |
| [Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status]. | Nederlands tijdschrift voor geneeskunde 20031018 |
| Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. | European journal of clinical pharmacology 20031001 |
| Oral direct thrombin inhibitors in clinical development. | Journal of internal medicine 20031001 |
| Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. | Journal of thrombosis and haemostasis : JTH 20031001 |
| Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. | European journal of heart failure 20031001 |
| Aging and coagulation. | Clinical advances in hematology & oncology : H&O 20031001 |
| Improving antithrombotic treatment in patients after myocardial infarction. | Lancet (London, England) 20030906 |
| Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. | Lancet (London, England) 20030906 |
| Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). | American heart journal 20030901 |
| Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. | European journal of clinical pharmacology 20030801 |
| The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. | Thrombosis research 20030715 |
| Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. | Thrombosis research 20030715 |
| Medical indications and considerations for future clinical decision making. | Thrombosis research 20030715 |
| Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20030701 |
| [New antithrombotic agents. Towards a new therapeutic plan]. | La Revue du praticien 20030515 |
| Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. | Journal of the American College of Cardiology 20030507 |
| Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. | Drug metabolism and disposition: the biological fate of chemicals 20030501 |
| The METHRO trials. | Expert opinion on investigational drugs 20030501 |
| Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. | European journal of clinical pharmacology 20030501 |
| 52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003. | International journal of clinical practice 20030501 |
| Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. | Journal of thrombosis and haemostasis : JTH 20030501 |
| Orally active direct thrombin inhibitors. | Seminars in vascular medicine 20030501 |
| [The first oral thrombin inhibitor. Competition to heparins and marcumar?]. | MMW Fortschritte der Medizin 20030306 |
| Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. | Drug metabolism and disposition: the biological fate of chemicals 20030301 |
| Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. | American heart journal 20030301 |
| Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. | Journal of the American College of Cardiology 20030219 |
| Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. | Thrombosis and haemostasis 20030201 |
| Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115 |
| [New anticoagulants -- their clinical significance]. | Therapeutische Umschau. Revue therapeutique 20030101 |
| Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. | Clinical pharmacokinetics 20030101 |
| [New and future antithrombotic agents in thrombo-embolic venous disease]. | La Revue du praticien 20030101 |
| No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. | Clinical pharmacokinetics 20030101 |
| No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. | Clinical pharmacokinetics 20030101 |
| Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. | Clinical pharmacokinetics 20030101 |
| Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. | Clinical pharmacokinetics 20030101 |
| No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. | Clinical pharmacokinetics 20030101 |
| Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. | Clinical pharmacokinetics 20030101 |
| A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. | Journal of thrombosis and haemostasis : JTH 20030101 |
| [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]. | Bulletin de l'Academie nationale de medecine 20030101 |
| Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation. | Pathophysiology of haemostasis and thrombosis 20030101 |
| Ximelagatran: a new oral anticoagulant. | Heart disease (Hagerstown, Md.) 20030101 |
| Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. | Lancet (London, England) 20021109 |
| Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. | The Israel Medical Association journal : IMAJ 20021101 |
| Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. | Annals of internal medicine 20021015 |
| Summaries for patients. Ximelagatran versus warfarin to prevent blood clots after knee replacement surgery. | Annals of internal medicine 20021015 |
| Traditional versus modern anticoagulant strategies: summary of the literature. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20021015 |
| Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. | Thrombosis research 20020815 |
| Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. | Thrombosis research 20020815 |
| [Anticoagulation: the present and the future]. | Hamostaseologie 20020801 |
| [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement]. | Hamostaseologie 20020801 |
| [Ximelagatran for treatment of venous thromboembolism]. | Hamostaseologie 20020801 |
| [Future potential indications for an oral thrombin inhibitor]. | Hamostaseologie 20020801 |
| Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. | Thrombosis and haemostasis 20020401 |
| A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. | Thrombosis and haemostasis 20020201 |
| Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. | Thrombosis and haemostasis 20020201 |
| Ximelagatran (AstraZeneca). | Current opinion in investigational drugs (London, England : 2000) 20020201 |
| Development and validation of a capillary electrophoresis method for ximelagatran assay and related substance determination in drug substance and tablets. | Journal of pharmaceutical and biomedical analysis 20020115 |
| [Two new very promising antithrombotic agents: pentasaccharide and ximelagatran]. | Revue medicale de la Suisse romande 20020101 |
| Therapeutic considerations in the management of patients with heparin-induced thrombocytopenia. | Progress in cardiovascular nursing 20020101 |
| Ximelagatran. Exanta, H 376, H 376/95, H 37695. | Drugs in R&D 20020101 |
| Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia. | Canadian journal of anaesthesia = Journal canadien d'anesthesie 20020101 |
| Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. | Archives of internal medicine 20011008 |
| Anticoagulation: the present and future. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20010701 |
| The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. | Thrombosis research 20010201 |